Selective Intestinal Decontamination in Advanced Chronic Heart Failure: A Pilot Trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background and aims: Endotoxin, derived from intestinal aerobic Gram-negative bacilli (AGNB), could be an important monocyte activator in chronic heart failure (CHF). The effect of selective decontamination of the digestive tract (SDD) on intracellular monocyte cytokine production, monocyte CD14 expression, circulating endotoxin and cytokines, and flow-mediated dilation (FMD) was studied in patients with severe CHF. Methods and results: Ten patients with CHF (NYHA class III–IV) were enrolled in a non-placebo controlled pilot trial involving the administration of SDD (polymyxin B, tobramycin) for 8 weeks. One patient was later excluded due to cardiac transplantation. Before treatment, after 4 and 8 weeks therapy, and 6 weeks post-treatment, monocyte CD14 expression, intracellular monocyte production of interleukin-1β [IL-1β], interleukin-6 [IL-6], tumour necrosis factor (TNF)-α with and without lipopolysaccharide (LPS) stimulation were measured. Concentrations of endotoxin and cytokines (IL-1β, IL-6, TNF-α) were also determined. AGNB in faeces, intestinal endotoxin and FMD were assessed at baseline, after 4 weeks of treatment and 6 weeks post-treatment. SDD eradicated intestinal AGNB (P<0.00001) and decreased faecal endotoxin concentrations (P<0.00001). There was a significant decline in monocyte CD14 expression (P=0.03) and in IL-1β (P=0.0001), IL-6 (P=0.02) and TNF-α (P=0.0002) production after 4 and 8 weeks of treatment in the basal state and for IL-1β (P=0.008) and IL-6 (P=0.005) after LPS stimulation. FMD significantly improved at 4 weeks and returned to baseline after treatment discontinuation (P=0.002). Circulating concentrations of endotoxin and cytokines remained unchanged. Conclusion: Reduction of the intestinal endotoxin pool led to a decrease in monocyte CD14 expression and intracellular cytokine production in patients with severe CHF. The improvement of peripheral endothelial function could be a marker of the anti-inflammatory effect of SDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J., Miller, O. I., Sullivan, I. D., Lloyd, J. K., & Deanfield, J. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)93147-f · Cited by 4,742
Torre-Amione, G., Kapadia, S., Benedict, C., Oral, H., Young, J. B., & Mann, D. L. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00589-7 · Cited by 1,211
Endotoxin and immune activation in chronic heart failure: a prospective cohort study
Niebauer, J., Volk, H.-D., Kemp, M., Dominguez, M., Schumann, R. R., Rauchhaus, M., Poole-Wilson, P. A., Coats, A. J., & Anker, S. D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09286-1 · Cited by 877
Self-citationPlasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure
Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., Niebauer, J., Hooper, J., Volk, H.-D., Coats, A. J. S., et al. (2000) · Circulation · doi:10.1161/01.cir.102.25.3060 · Cited by 810
Self-citationElevated soluble CD14 receptors and altered cytokines in chronic heart failure
Anker, S. D., Egerer, K. R., Volk, H.-D., Kox, W. J., Poole-Wilson, P. A., & Coats, A. J. S. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00159-8 · Cited by 392
Self-citation
Cited by
Dietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789
Altered intestinal function in patients with chronic heart failure
Sandek, A., Bauditz, J., Swidsinski, A., Buhner, S., Weber-Eibel, J., von Haehling, S., Schroedl, W., Karhausen, T., Doehner, W., Rauchhaus, M., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.016 · Cited by 661
“Recent studies on selective decontamination of the gut in CHF patients have resulted in a decrease in some inflammatory markers underscoring the potential importance of gut bacteria as one source of inflammation in CHF (47).”
BackgroundSelf-citationTNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure
Kleinbongard, P., Heusch, G., & Schulz, R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.002 · Cited by 409
Trøseid, M., Andersen, G. Ø., Broch, K., & Hov, J. R. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102649 · Cited by 408
TMAO: how gut microbiota contributes to heart failure
Zhang, Y., Wang, Y., Ke, B., & Du, J. (2021) · Translational Research · doi:10.1016/j.trsl.2020.08.007 · Cited by 296
Systemic inflammation in heart failure – The whys and wherefores
Yndestad, A., Kristian Damås, J., Øie, E., Ueland, T., Gullestad, L., & Aukrust, P. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9196-2 · Cited by 294
“have recently showed that selective intestinal decontamination attenuates the intestinal endotoxin pool and leads to a decrease in monocyte CD14 expression and intracellular cytokine production in patients with severe chronic HF [48].”
BackgroundZhang, Y., Zhang, S., Li, B., Luo, Y., Gong, Y., Jin, X., Zhang, J., Zhou, Y., Zhuo, X., Wang, Z., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab114 · Cited by 272
Immune Mechanisms in Heart Failure
Zhang, Y., Bauersachs, J., & Langer, H. F. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.942 · Cited by 262
Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis
Nagatomo, Y., & Tang, W. H. W. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.09.017 · Cited by 259
“1 3 cytokines in patients with HF and improved flow-mediated dilation, a marker of endothelial function [41].”
BackgroundInfluentialCostanza, A. C., Moscavitch, S. D., Faria Neto, H. C. C., & Mesquita, E. T. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.11.034 · Cited by 182
Conraads, V. M., Denollet, J., De Clerck, L. S., Stevens, W. J., Bridts, C., & Vrints, C. J. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.10.013 · Cited by 119
Self-citationSilvestri, L., de la Cal, M. A., & van Saene, H. K. F. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2690-1 · Cited by 111
“Patients who were free from AGNB following the enteral intake of polymyxin and tobramycin were able to control generalised inflammation [126].”
Silvestri, L., van Saene, H. K. F., Zandstra, D. F., Marshall, J. C., Gregori, D., & Gullo, A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d9db8c · Cited by 78
“Additionally, the enteral antimicrobials polymyxin/tobramycin prevent and, if already present, eradicate gut overgrowth of abnormal flora (15) and reduce the fecal endotoxin load by a factor of 10(4) (16, 17).”
BackgroundDenollet, J., Vrints, C. J., & Conraads, V. M. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.10.015 · Cited by 58
Self-citation
Metadata
- Authors
- Conraads, V. M., Jorens, P. G., De Clerck, L. S., Van Saene, H. K., Ieven, M. M., Bosmans, J. M., Schuerwegh, A., Bridts, C. H., Wuyts, F., Stevens, W. J., Anker, S. D., Rauchhaus, M., & Vrints, C. J.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-01
- Volume
- 6
- Issue
- 4
- Pages
- 483-491
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2117268669
- Cited by
- 110
- References
- 5
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.